Eastern Health

Running trials

• Recruiting

  Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO Study

  NCT07916727· Austin Health· Source

• Not yet recruiting

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

  NCT07055542· University of Melbourne· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  NCT06850727· Phase 2· Odyssey Therapeutics, Inc.· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Eikon Therapeutics· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

  NCT06191848· Phase 4· University of Melbourne· Source

• Active, not recruiting

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

  NCT05788081· Phase 2· Olivia Newton-John Cancer Research Institute· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Active, not recruiting

  Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

  NCT05694936· Phase 2· Australasian Gastro-Intestinal Trials Group· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  The Australian HCV Point-of-Care Testing Program

  NCT05042544· Kirby Institute· Source

• Active, not recruiting

  RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

  NCT05862051· Australasian Gastro-Intestinal Trials Group· Source

• Active, not recruiting

  Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

  NCT04962126· Phase 2· Olivia Newton-John Cancer Research Institute· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

  NCT03245021· Phase 1· Dr. Eliza Hawkes· Source

• Active, not recruiting

  Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

  NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis2 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Crohn's disease1 recruiting
• Hepatitis C1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

  NCT03244176· Early phase 1· Austin Health· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Cannabis use disorder12 works · 0 trials
• Borderline personality disorder11 works · 0 trials
• Alcohol use disorder10 works · 0 trials
• Cocaine and methamphetamine use disorder3 works · 0 trials